192 results
Page 4 of 10
8-K
EX-99.1
l981gzni8kldpsxvc
1 Dec 14
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
12:00am
8-K
EX-10.3
0tvaw06wof8ydy 2a
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.1
bkg1w ksb
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.5
vny8q
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.4
qpq 7qlx5tyzz2yz
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.1
qnhkx33lrn7fi
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.8
3edbggug iai2wjmac
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.4
sz86 n7m1ak
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.7
fg9x2d nbiojxjbica9
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.5
erh7on
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am